FY2025 EPS Forecast for Benitec Biopharma Raised by Analyst

Benitec Biopharma Inc. (NASDAQ:BNTC) – HC Wainwright lifted their FY2025 earnings estimates for Benitec Biopharma in a research report issued on Monday, May 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($1.33) per share for the year, up from their previous forecast of ($1.55). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q4 2025 earnings at ($0.25) EPS.

Separately, JMP Securities restated a “market outperform” rating and issued a $20.00 target price on shares of Benitec Biopharma in a research note on Thursday, May 15th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $24.71.

Benitec Biopharma Trading Down 1.9%

Shares of BNTC stock opened at $13.66 on Wednesday. The company has a market capitalization of $349.70 million, a PE ratio of -9.05 and a beta of 0.34. The firm has a fifty day simple moving average of $13.62 and a 200-day simple moving average of $12.08. Benitec Biopharma has a twelve month low of $5.74 and a twelve month high of $16.90.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.12.

Institutional Trading of Benitec Biopharma

Several institutional investors have recently added to or reduced their stakes in BNTC. Franklin Resources Inc. raised its holdings in shares of Benitec Biopharma by 269.0% during the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company’s stock worth $37,123,000 after purchasing an additional 2,142,643 shares during the period. Geode Capital Management LLC raised its holdings in shares of Benitec Biopharma by 134.7% during the fourth quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company’s stock worth $2,490,000 after purchasing an additional 113,109 shares during the period. MYDA Advisors LLC acquired a new stake in shares of Benitec Biopharma during the fourth quarter worth $632,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company’s stock worth $24,913,000 after purchasing an additional 1,131,129 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 13,425 shares during the period. 52.19% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 900,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average cost of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the acquisition, the director now directly owns 8,793,245 shares of the company’s stock, valued at approximately $114,312,185. The trade was a 11.40% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.